TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35397622
Drug: 90 g/day low-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g/day low-carbohydrate diet (LCD)
Study: 33832346
Drug: Fluoropyrimidine (FP)
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluoropyrimidine (FP) therapy
Study: 35816053
Drug: BNT162b2 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 as second dose
Study: 35816053
Drug: ChAdOx1 nCoV‐19
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV‐19 as second dose
Study: 35816053
Drug: CoronaVac as
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac as second dose
Study: 35816053
Drug: Heterologous two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous two-dose schedules
Study: 33628086
Drug: Pyridostigmine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 0.15 mg/kg + glycopyrrolate 0.4 mg (control group)
Study: 32197627
Drug: Tailored cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored cognitive behavioural therapy
Study: 33264516
Drug: Bimagrumab 30
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 30 mg/kg
Study: 33264516
Drug: Bimagrumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab (both doses)
Study: 32800842
Drug: Home BP
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home BP treatment
Study: 32800842
Drug: Predialysis BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predialysis BP treatment
Study: 34076379
Drug: Passiflora incarnata
Normalized name: Passiflora incarnata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora incarnata L
Study: 35726085
Drug: Digital therapeutics
Normalized name: digital therapeutics, amblyopia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital therapeutics (DTx) + guideline-based lifestyle modification consultation treatment as usual (TAU)
Study: 35545190
Drug: Computer-guided sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided sodium hyaluronate injections
Study: 35545190
Drug: Conventional sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sodium hyaluronate injections
Study: 33576545
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg/Acetaminophen 650 mg
Study: 33196737
Drug: USCCM cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: USCCM cream and serum pre‐ and post‐ ablative resurfacing
Study: 33196737
Drug: Vehicle pre‐procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle pre‐procedure cream
Study: 34665204
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus nicotine patch for 12 weeks
Study: 34665204
Drug: Varenicline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline monotherapy for 12 weeks
Study: 34665204
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus nicotine patch for 24 weeks
Study: 34665204
Drug: Varenicline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline monotherapy for 24 weeks
Study: 32304283
Drug: Metformin/sitagliptin dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/sitagliptin dual therapy for 16 weeks
Study: 32304283
Drug: Metformin/sitagliptin triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/sitagliptin triple therapy for 24 weeks
Study: 32720187
Drug: Technosphere® Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere® Insulin (TI)
Study: 32720187
Drug: Technosphere inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere inhalation powder without insulin (TP; placebo)
Study: 32720187
Drug: Active-comparator treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-comparator treatment
Study: 32720187
Drug: Active TI
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TI therapy
Study: 36622539
Drug: Tecarfarin 30
Normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin 30 mg
Study: 34218304
Drug: Montelukast (MON)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (MON) 10 mg once daily
Study: 35653732
Drug: Dual-hormone algorithm-assisted
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual-hormone algorithm-assisted insulin delivery (DH-AID)
Study: 35653732
Drug: Single-hormone algorithm-assisted
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-hormone algorithm-assisted insulin delivery (SH-AID)
Study: 33524314
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300 mg orally once daily for 3 years)
Study: 33524314
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral once daily for 3 years)
Study: 33316362
Drug: Adaptive planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adaptive planning (AP) using a minimization algorithm, 36 Gy in 6 weekly fractions.
Study: 33316362
Drug: Standard planning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard planning (SP), 36 Gy in 6 weekly fractions.
Study: 35578194
Drug: Stabilizing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilizing group treatment (20 sessions, add-on to individual therapy)
Study: 35578194
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy alone
Study: 35578194
Drug: Stabilizing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilizing group treatment
Study: 33710658
Drug: Conventional saphenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional saphenous vein graft preparation with low-pressure distension
Study: 33496068
Drug: Candida antigen
Normalized name: Candida antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida antigen (0.1 mL of Candida albicans antigen injected monthly in one patch of alopecia)
Study: 33496068
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid (0.1 mL of triamcinolone acetonide injected monthly in all alopecia patches)
Study: 33023521
Drug: Guided counseling
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided counseling (monthly for four consecutive months)
Study: 32315537
Drug: Antidepressant Treatment
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Treatment Record (ATR) classification level 1
Study: 32315537
Drug: Antidepressant Treatment
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Treatment Record (ATR) classification level 2
Study: 32315537
Drug: Antidepressant Treatment
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Treatment Record (ATR) classification level ≥3
Study: 32315537
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with serotonin norepinephrine reuptake inhibitors (SNRIs)
Study: 32315537
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with dopamine norepinephrine reuptake inhibitors (DNRIs)
Study: 32315537
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with mixed dopamine serotonin receptor antagonists
Study: 35707522
Drug: Integrative Acupuncture
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative Acupuncture and Moxibustion (iAM) treatment
Study: 35707522
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg once a day)
Study: 35707522
Drug: Active/sham iAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active/sham iAM treatment (three times per week)
Study: 34283799
Drug: Classical music
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical music played during treatment
Study: 34283799
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music played during treatment
Study: 34551581
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) - 40 ml 0.125% SB plus 20 ml of LB
Study: 33218524
Drug: Daily aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily aerobic walking exercise (DAWE)
Study: 32166831
Drug: Clonidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (3 µg/kg intravenous bolus)
Study: 32173808
Drug: Ropivacaine (R)
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine (R) 2mg/kg with ropivacaine: 4.75 mg/ml in wound infiltration (WI)
Study: 33435969
Drug: Three-part equal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-part equal incentive for home testing, attendance of weekly telephone education classes, and HbA1c reduction at 3 months (Group 3)
Study: 35927806
Drug: Active 10Hz
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active 10Hz rTMS (n=63) in CC homozygotes
Study: 36082412
Drug: Light Dark
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light Dark Therapy (LDT)
Study: 33002437
Drug: Salvage radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiotherapy (64 Gy in 32 fractions triggered by PSA of 0.20 ng/mL or more)
Study: 34848508
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow rhinothermy (rNHF) - 100% humidified air delivered at 35 L/min and 41°C for 2 hours daily for 5 days
Study: 34848508
Drug: Sham rhinothermy
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rhinothermy - 100% humidified air delivered at 10 L/min and 31°C for 10 min daily for 5 days
Study: 34587648
Drug: L-NMMA (NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (NOS inhibitor)
Study: 33675264
Drug: Hemp-based nutraceutical
Normalized name: hemp
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp-based nutraceutical product (Gs Formula; GF) at 160 g/day (LO)
Study: 33675264
Drug: Hemp-based nutraceutical
Normalized name: hemp
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp-based nutraceutical product (Gs Formula; GF) at 480 g/day (HI)
Study: 33675264
Drug: Hemp-based nutraceutical
Normalized name: hemp
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp-based nutraceutical product (Gs Formula; GF) at 0 g/day (CON)
Study: 32791704
Drug: Sogyeonghwalhyeol-tang (SGHH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sogyeonghwalhyeol-tang (SGHH) with Chuna manual therapy (CMT)
Study: 32791704
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Chuna manual therapy (CMT)
Study: 34900185
Drug: Chrysanthemum extract
Normalized name: Chrysanthemum indicum top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysanthemum extract 400 mg/day (200 mg/day, twice/day)
Study: 36459070
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neurodevelopmental treatment and talocrural joint MWM)
Study: 33267762
Drug: Intravitreal Dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Dexamethasone implant (IVD) 0.7 mg, single dose
Study: 33267762
Drug: Intravitreal Ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Ranibizumab injection (IVR) 0.3 mg, 3 doses (monthly)
Study: 33267762
Drug: Intravitreal Dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Dexamethasone implant (IVD)
Study: 33267762
Drug: Intravitreal Ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Ranibizumab injection (IVR)
Study: 33631355
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg/6 months)
Study: 32282491
Drug: Aromatherapy (lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (lavender oil) inhalation administered half hour before sleep every day for a month.
Study: 32282491
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration applied to the control group.
Study: 36422204
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone (1 mg/mL)
Study: 36422204
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac (0.9 mg/mL)
Study: 32066489
Drug: Ticagrelor (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (loading dose 180 mg, maintenance dose 90 mg bid)
Study: 32066489
Drug: Clopidogrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading dose 600 mg, maintenance dose 75 mg)
Study: 33655799
Drug: Weekly aerobic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly aerobic exercises associated with nutritional counseling
Study: 32271583
Drug: Ultraviolet-Ozone (UVO)
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet-Ozone (UVO) treatment applied to drug-coated balloons (DCBs) with urea-paclitaxel coating.
Study: 32271583
Drug: Standard drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug-coated balloons (DCBs) without UVO treatment.
Study: 34587702
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose red yeast rice (200 mg/day) containing 2 mg monacolin K
Study: 33734864
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tamoxifen
Study: 36064438
Drug: AutoKinetics dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AutoKinetics dosing for ciprofloxacin
Study: 36064438
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing for ciprofloxacin (Control)
Study: 34265777
Drug: Attention Control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Control followed by Cognitive Processing Therapy (CPT)
Study: 34712679
Drug: Jinhua Qinggan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jinhua Qinggan granules combined with antiviral drugs
Study: 34712679
Drug: Antiviral drugs
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs alone (Western medicine group)
Study: 36013168
Drug: Lung ultrasound-guided
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound-guided therapy (LUS)
Study: 36086764
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 ng/mL with midazolam
Study: 36086764
Drug: Remifentanil 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2.0 ng/mL with midazolam
Study: 33181560
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) with a flow rate of 2 L kg‐1 min‐1
Study: 32170769
Drug: Bortezomib consolidation
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib consolidation (BC) - 1.3 mg/m2 IV days 1, 4, 8, 11 of a 3-week cycle for four cycles
Study: 32170769
Drug: Bortezomib maintenance
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib maintenance (BM) - 1.6 mg/m2 IV once weekly × 4 every 8 weeks for 18 months
Study: 33466606
Drug: Percussion Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percussion Therapy (PT)
Study: 32823974
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplement (Redoxon® VI, Singapore) taken daily for 12 weeks
Study: 32823974
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (inactive) taken daily for 12 weeks
Study: 32979077
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d DHA for 6 months
Study: 32532761
Drug: Micropulse laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micropulse laser therapy (MLT)
Study: 33444588
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 fatty acid (1 g/d)
Study: 33413588
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5-20 mg/kg
Study: 33683325
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of high-dose amoxicillin followed by 5 days of placebo
Study: 33683325
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of high-dose amoxicillin followed by a different formulation of 5 days of high-dose amoxicillin
Study: 32388274
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g of cod fillets per week
Study: 35170539
Drug: Adjuvant steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant steroid therapy (10-12 weeks)
Study: 35170539
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine postoperative treatment)
Study: 34798060
Drug: Cagrilintide 0.3-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide 0.3-4.5 mg
Study: 34798060
Drug: Cagrilintide 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide 4.5 mg
Study: 34233667
Drug: Antibiotic sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic sensitivity to Cefazolin
Study: 34233667
Drug: Antibiotic sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic sensitivity to Tetracycline
Study: 35388666
Drug: Oral tebipenem
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tebipenem pivoxil hydrobromide (600 mg every 8 hours)
Study: 35388666
Drug: Intravenous ertapenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ertapenem (1 g every 24 hours)
Study: 35388666
Drug: Oral tebipenem
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tebipenem pivoxil hydrobromide
Study: 35388666
Drug: Intravenous ertapenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ertapenem
Study: 36145064
Drug: Fava bean
Normalized name: Fava Bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fava bean protein (FBP) 0.33 g·kg‐1
Study: 32424935
Drug: 1.8 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/d liraglutide
Study: 35640182
Drug: Combined orthodonto-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orthodonto-surgical treatment
Study: 32579811
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 to 300 mg daily)
Study: 35506425
Drug: Extra time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra time with alcohol and drug nurses
Study: 33863276
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Study: 36333742
Drug: music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: music therapy activities
Study: 35545225
Drug: Rapid Intermittent
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Intermittent Bolus (RIB) of electrolyte-free solution for 1 hour
Study: 35545225
Drug: Slow Continuous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Continuous Infusion (SCI) of electrolyte-free solution continuously
Study: 36203215
Drug: Family-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive behavioural therapy (FCBT)
Study: 33477443
Drug: Mohana Choorna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mohana Choorna (Ayurvedic herbal preparation)
Study: 33322022
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of epigallocatechin gallate (EGCG) and 60 mL of coconut oil daily for 4 months
Study: 32150661
Drug: Everolimus at
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus at a dose of 6 mg/m2
Study: 34157162
Drug: FCL combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCL combined with intradermal injection of plasma gel
Study: 34157162
Drug: FCL combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCL combined with topical application of plasma gel
Study: 34157162
Drug: FCL monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCL monotherapy
Study: 39491396
Drug: Darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600 mg twice daily
Study: 36081217
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 26 weeks
Study: 35772622
Drug: Antimicrobial Photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial Photodynamic Therapy with methylene blue (300 µmol/L)
Study: 35772622
Drug: Antimicrobial Photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial Photodynamic Therapy with curcumin (8 µmol/L)
Study: 34607196
Drug: Neuroaspis PLP10™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroaspis PLP10™ (20 ml once daily for 30 months)